The purpose of this study is to compare the effectiveness, tolerability, and efficacy of the currently available atypical antipsychotic drugs olanzapine (2.5-20 mg/day), quetiapine (100-800 mg/day) and risperidone (0.5-4 mg/day) in patients with schizophrenia, schizophreniform disorder, or schizoaffective disorder who are experiencing their first psychotic episode.

Condition	Treatment or Intervention	Phase
Schizophrenia Psychotic Disorders Mental Health Mental Disorders	Drug: Olanzapine, risperidone	Phase IV

Ages Eligible for Study:  16 Years   -   40 Years,  Genders Eligible for Study:  Both

Criteria

Inclusion Criteria:

• Patients must meet criteria for schizophreniform disorder, schizophrenia, or schizoaffective disorder with psychotic symptoms lasting 1-60 months
• Psychotic symptoms must have persisted at least one month, and not more thn 5 years (60 months)
• Patients must have no previous history of drug treatment (greater than a total of 16 weeks) with antipsychotics

Exclusion Criteria:

• Patients with history of psychotic disorder with recovery period of at least 3 months
• Female patients who are pregnant or nursing
• Patients with a known history of mental retardation

California
      Stanford,  California,  United States
Florida
      Miami,  Florida,  United States
Georgia
      Atlanta,  Georgia,  United States
      Augusta,  Georgia,  United States
Illinois
      Chicago,  Illinois,  United States
Louisiana
      Shreveport,  Louisiana,  United States
Massachusetts
      Boston,  Massachusetts,  United States
      Worcester,  Massachusetts,  United States
Minnesota
      Minneapolis,  Minnesota,  United States
Missouri
      St. Louis,  Missouri,  United States
Nevada
      Las Vegas,  Nevada,  United States
New York
      Brooklyn,  New York,  United States
      New York,  New York,  United States
North Carolina
      Charlotte,  North Carolina,  United States
      Butner,  North Carolina,  United States
      Chapel Hill,  North Carolina,  United States
Ohio
      Kettering,  Ohio,  United States
      Cincinnati,  Ohio,  United States
      Cleveland,  Ohio,  United States
Pennsylvania
      Philadelphia,  Pennsylvania,  United States
Texas
      Conroe,  Texas,  United States
      San Antonio,  Texas,  United States
      Research Site, Dallas,  Texas,  United States
Utah
      Salt Lake City,  Utah,  United States
Canada, Alberta
      Calgary,  Alberta,  Canada
Canada, Nova Scotia
      Halifax,  Nova Scotia,  Canada

Study ID Numbers:  5077IL/0114
Record last reviewed:  April 2004
Last Updated:  October 13, 2004
Record first received:  May 2, 2002
ClinicalTrials.gov Identifier:  NCT00034892
Health Authority: United States: Food and Drug Administration
ClinicalTrials.gov processed this record on 2005-04-08